Aug 18: Regeneron Pharmaceuticals Veopoz (pozelimab) secured FDA approval as the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms
Multiple publications from Zagreb group, 2009 to 2020 range
As no significant differences in serum homocysteine, cystathionine (Figures 4 and 5) or serine levels [60, 69, 70, 75] were observed in children with autistic disorder compared to those without, it can be inferred that the low levels of cysteine may be caused by decreased cystathione lyase activity and/or increased utilisation of sulphate and/or taurine and/or lower dietary intake or absorption of cysteine in children with autistic disorder
La disminucin del FGe medio a las 52 semanas fue menor en los grupos de tratamiento con dosis altas (1,5mg) y bajas de dulaglutida (0,75mg) (ambos 0,7ml/min/1,73m2) vs
10.1016/j.ejphar.2024.176706 Eur
Under that setup, generic substitution doesn't happen automatically, it requires a deliberate plan design decision
